Bayer AG (BAYRY) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The RELIEF study is an upcoming U.S. observational study run by Bayer to track how women use elinzanetant for menopause-related hot flashes and sleep issues in routine care. It will follow about 1,500 postmenopausal women to see who starts the drug, how their symptoms change, and how treatment affects day-to-day life, giving investors real-world insight beyond earlier trials.
Elinzanetant is a non-hormonal oral drug designed to ease vasomotor symptoms such as hot flashes and night sweats. The study does not add extra procedures or dosing rules, so results should show how the medicine performs when prescribed by regular doctors rather than under strict trial controls.
The design is prospective and observational, meaning researchers watch outcomes over time without assigning treatments. There is no randomization or placebo group, and the single cohort model makes the results easier to interpret for real-world use, but it will not prove cause and effect the way a classic randomized trial might.
The study has not yet started recruiting, with first submission recorded as Feb. 27, 2026, and the latest update on Apr. 16, 2026, signaling active set-up work. Key future dates will include primary and final completion, when early real-world effectiveness and safety data will become available and could act as trading catalysts.
For Bayer (BAYRY), a strong non-hormonal menopause asset can open a large and under-served market, supporting long-term revenue diversification and sentiment around its pharma pipeline. Investors should also track competitors in women’s health and non-hormonal VMS therapies, as positive real-world readouts may reset expectations for the whole segment and influence valuations across the space.
The RELIEF study is not yet recruiting but has been recently updated, and further details are available on the ClinicalTrials portal.
To learn more about BAYRY’s potential, visit the Bayer AG drug pipeline page.